Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Scleroderma renal crisis
Nilanjana Bose
, Andres Chiesa-Vottero
, Soumya Chatterjee
Research output
:
Contribution to journal
›
Review article
›
peer-review
106
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Scleroderma renal crisis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Scleroderma Renal Crisis
100%
Risk Factors
33%
Scleroderma Systemic
22%
Angiotensin-converting Enzyme Inhibitor (ACEi)
22%
Scleroderma
22%
Systemic Sclerosis
22%
Corticosteroids
11%
Treatment Options
11%
Adverse Outcomes
11%
Hypertension
11%
Pathophysiology
11%
Blood Flow
11%
Recurring
11%
Kidney
11%
Insults
11%
Clinical Manifestations
11%
Hyperplasia
11%
Clinical Outcomes
11%
Congestive Heart Failure
11%
End-stage Renal Disease
11%
Improved Survival
11%
Clinical Diagnosis
11%
Prognostic Factors
11%
Endothelial Injury
11%
Transplanted Kidney
11%
PubMed Search
11%
Prompt Diagnosis
11%
Anti-RNA Polymerase III Antibodies
11%
Dialysis
11%
Cyclosporine
11%
Cardiac Complications
11%
Prompt Treatment
11%
Renal Transplantation
11%
Hyperreninemia
11%
Intimal Proliferation
11%
Thrombocytopenia
11%
Survival Data
11%
Arrhythmia
11%
Renal Arteriole
11%
Diagnosis Treatment
11%
New Onset
11%
Microangiopathic Hemolytic Anemia
11%
Pericardial Effusion
11%
Kidney Disease Progression
11%
Normal Blood Pressure
11%
Large Joints
11%
Etiopathogenesis
11%
Initial Description
11%
Juxtaglomerular Apparatus
11%
Joint Contracture
11%
Skin Thickening
11%
Renal Prognosis
11%
Renal Crisis
11%
Malignant Hypertension
11%
Prognostic Survival
11%
Medicine and Dentistry
Scleroderma
100%
ACE Inhibitor
15%
Systemic Scleroderma
15%
Malignant Hypertension
15%
Blood Pressure
7%
Pathophysiology
7%
Blood Flow
7%
Hyperplasia
7%
End Stage Renal Disease
7%
Renal Failure
7%
Prognostic Factor
7%
Endothelium Injury
7%
Adverse Outcome
7%
Kidney Transplantation
7%
Cyclosporine
7%
Hyperreninemia
7%
Artery Intima Proliferation
7%
Arteriole
7%
Congestive Heart Failure
7%
Thrombocytopenia
7%
Cardiac Dysrhythmia
7%
Thrombotic Thrombocytopenic Purpura
7%
Pericardial Fluid
7%
DNA Directed RNA Polymerase III
7%
Juxtaglomerular Apparatus
7%
Joint Contracture
7%
Treatment Option
7%
Pharmacology, Toxicology and Pharmaceutical Science
Scleroderma
100%
Dipeptidyl Carboxypeptidase Inhibitor
15%
Systemic Sclerosis
15%
Malignant Hypertension
15%
Adverse Outcome
7%
Pathophysiology
7%
Hyperplasia
7%
Congestive Heart Failure
7%
End Stage Renal Disease
7%
Endothelium Injury
7%
Ciclosporin
7%
Thrombocytopenia
7%
Heart Arrhythmia
7%
Kidney Failure
7%
Thrombotic Thrombocytopenic Purpura
7%
DNA Directed RNA Polymerase III
7%
Hyperreninemia
7%
Artery Intima Proliferation
7%
Pericardial Effusion
7%
Joint Contracture
7%